GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3359)

  • GC72378 structure
    GC72378Neihulizumab
    CAS: 2158362-38-8
    Purity: >98.00%

    Neihulizumab (ALTB-168) 는 면역검사점 격동항체로 사람 CD162 (PSGL-1) 와 결합하여 활성화 T세포가 하향조정된다.

  • GC72386 structure
    GC72386Afelimomab
    CAS: 156227-98-4
    Purity: >99.00%

    Afelimomab (MAK 195F)는 항종양 괴사인자 F (ab') 2 단일 클론 항체 조각입니다.

  • GC72419 structure
    GC72419Iscalimab
    CAS: 2031153-61-2
    Purity: >99.00%

    Iscalimab (CFZ-533) 는 CD40을 표적으로 하는 비고갈성 IGg1 단일클론항체(KD:0.3nM)이다.

  • GC72423 structure
    GC72423Letolizumab
    CAS: 1450981-87-9
    Purity: 95.00%

    Letolizumab (BMS-986004)는 CD40L을 목표로 하는 단일 클론 항체로, Fc 결합 및 보완 고정을 포함한 이펙터 기능이 결여된 돌연변이 IgG1을 발현하기 위해 생산된다.

  • GC72440 structure
    GC72440Ozoralizumab
    CAS: 1167985-17-2
    Purity: >99.00%

    Ozoralizumab (ATN-103)은 anti-TNF α 항체 서였다.

  • GC72463 structure
    GC72463Rulonilimab
    CAS: 2417124-95-7
    Purity: 95.00%

    Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity.

  • GC72511 structure
    GC72511L-Cystathionine dihydrochloride
    CAS: 61125-50-6
    Purity: >99.50%

    L-Cystathionine dihydrochloride는 비단백질 티오에테르이며 황함유 아미노산의 대사 상태와 관련된 주요 아미노산입니다.

  • GC72575 structure
    GC72575L-Glutamic acid monosodium (hydrate)
    CAS: 6106-04-3
    Purity: >98.00%

    L-Glutamic acid monosodium (hydrate)는 영양 첨가제 및 조미료입니다.

  • GC72791 structure
    GC72791Delmitide acetate
    CAS: 501019-16-5
    Purity: >98.00%

    Delmitide acetate 는 구복 활성 d-이구체 십펩타이드로 강력한 항염 활성을 가지고 있다.

  • GC72792 structure
    GC72792Cyclopentenylcytosine
    CAS: 90597-22-1
    Purity: >99.00%

    Cyclopentenylcytosine (CPC) 는 CTP 합성효소를 억제하여 백혈병 세포의 테트로포닌산(CTP)과 디옥시포닌삼인산염(dCTP) 수준을 낮추는 뉴클레오티드 유사물이다.

  • GC72803 structure
    GC72803Aspidin BB
    CAS: 584-28-1
    Purity: >98.00%

    Aspidin BB는 phloroglucinol 유도체로, Dryopteris championii의 공중 부분에서 분리 될 수 있습니다.

  • GC72817 structure
    GC72817BAI1 hydrochloride
    CAS: 329349-20-4
    Purity: >99.00%

    BAI1 hydrochloride는 선택적 세포 사멸 인자 BAX 알로스테릭 억제제이다.

  • GC72824 structure
    GC72824KX2-361
    CAS: 897016-26-1
    Purity: >99.00%

    KX2-361 (KX-02)는 Src 효소와 마이크로 튜브 단백질 중합 억제제입니다.

  • GC72835 structure
    GC72835NSC260594
    CAS: 906718-66-9
    Purity: >96.00%

    NSC260594세포 사멸을 유도하다.

  • GC72851 structure
    GC72851Belapectin
    CAS: 1980787-47-0
    Purity: >99.00%

    Belapectin (GR-MD-02)는 Galectin-3 (Gal-3) 억제제입니다.

  • GC72858 structure
    GC72858Avenanthramide A
    CAS: 108605-70-5
    Purity: >99.00%

    Avenanthramide A은 귀리(Avena sativa L.)에서 발견할 수 있는 ptoalexin의 일종이다.

  • GC72862 structure
    GC72862Erasin
    CAS: 2256056-21-8
    Purity: >95.00%

    Erasin 는 강력한 엘로티닙 항성 옹색 STAT3 억제제로서 STAT3와 STAT1에 대한 IC50은 각각 9.7과 24 μM이다.

  • GC72863 structure
    GC72863PZ703b TFA
    Purity: >98.00%

    PZ703b TFA는 방광암 연구를 위해 세포 사멸을 유도하고 암세포 증식을 억제하는 Bcl-xl PROTAC 분해 물질입니다.

  • GC72864 structure
    GC72864PZ703b hydrochloride
    Purity: >99.00%

    PZ703b hydrochloride는 apoptosis를 유도하고 암세포 증식을 억제하는 Bcl-xl PROTAC 분해제입니다.

  • GC72868 structure
    GC72868AZA197
    CAS: 1249398-09-1
    Purity: >98.00%

    AZA197는 Cdc42의 선택적 소분자 억제제이다.

  • GC72875 structure
    GC72875Justicidin A
    CAS: 25001-57-4
    Purity: >99.00%

    Justicidin A Justicia procumbens에서 분리 될 수있는 천연 산물입니다.

  • GC72878 structure
    GC72878UCD38B hydrochloride
    CAS: 1115177-19-9
    Purity: >99.00%

    UCD38B hydrochloride은 셀 permeant, 경쟁력 있는 효소와 uPA 억제 제7 μ M의 IC50 값이다.

  • GC72892 structure
    GC72892Oblimersen sodium
    Purity: >98.00%

    Oblimersen sodium 는 BCL-2 RNA에 대한 BCL-2 억제제입니다.

  • GC72910 structure
    GC72910DD1
    CAS: 187585-11-1
    Purity: >99.00%

    DD1 프로테아제 억제제, 표적 급성 골수계 백혈병(AML) 사망 과정 중 Bax 활성화와 P70S6K 분해.